In summary, these findings suggest that terazosin inhibits the MST1‐Foxo3a signalling pathway, thereby ameliorating hyperglycemia and obesity in NAFPD mice, and facilitating the restoration of pancreatic β‐cell function. This evidence concerns the gene FOXO3 and Obesity.